Thank you for donating!

You can donate using the following services.

Research

Alongside providing support and care for those living with or affected by Niemann-Pick disease, NPUK also provides information relating to research. NPUK shares knowledge, expertise and works in partnership and collaboration with other not-for-profit organisations, medical authorities and scientific institutions across the world, in order to facilitate progress towards therapeutic interventions for the Niemann-Pick disease.

Where possible, NPUK also funds appropriate research in order to improve medical and scientific knowledge and promote understanding of the disease. The results are often shared amongst our community of families at the annual family conference we hold every September. It is through this medical research and clinical trials that we will find innovative new ways in which to better manage Niemann-Pick disease.

Research

Support us

Latest news

25.08.16

Take on the Challenge of a Lifetime from 10,000 ft!

Take on the challenge of a lifetime from 10,000 ft! Enjoy the exhilarating and unforgettable feeling of a skydive - flying through the clouds from over 10, 000 ft at up to 120 mph! Niemann-Pick UK are looking for thrill-seeking fundraisers to take on this once in a lifetime challenge and if you raise enough sponsorship, you can jump for free! You will be strapped to your qualified British Parachute Association tandem instructor who does all the hard work for you, leaving you to enjoy the invigorating feeling of freefalling before gliding to the ground!

Read more

25.08.16

CTD Holdings to Host Webinar to Provide Update on Trappsol® Cyclo™ Drug Development Program for Treatment of Niemann-Pick Disease Type C

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will host a webinar to provide details of the Company’s recently initiated Phase I clinical trial in the U.S. and Phase I/II clinical trial in the EU, both evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs.

Read more
View all news Subscribe